Indian Court Dismisses Teva’s Plea To Halt Natco’s Generic Copaxone Exports
This article was originally published in PharmAsia News
A two-year patent infringement case reached a conclusion with the Delhi High Court favoring Natco in a dispute over generic versions of Teva’s top-selling MS drug. If the court had sided with Teva, launch plans for the United States may have been delayed for Natco’s partner Mylan.
You may also be interested in...
FDA “has not to date had any questions that would indicate our application is off track,” CEO Wheeler says as Momenta and partner Sandoz gear up for the launch.
Federal Circuit finds claims covering Copaxone’s latest expiring patent are invalid; Mylan says it plans to launch its generic of the MS drug in May 2014.
Indian Government Denies Patent Application For Copaxone; Natco Pharma Says Obstacles Removed For Supply Of Generic Version Worldwide
MUMBAI - In a decision that could trigger a bigger battle, the Indian Patent Office has denied a patent application filed by an Israeli company for Copaxone(glatiramer), an innovative drug used in the treatment of multiple sclerosis